Schizophrenia 1 - Clinical (1)

[P138] Associations of clozapine available institution and the diagnosis of subgroups about treatment-resistant schizophrenia or not with a higher rate of antipsychotic monotherapy and lower other concomitant psychotropics in overall schizophrenia treatment: A real-world nationwide study.

*Shinichiro Ochi¹, Fumitoshi Kodaka², Naomi Hasegawa³, Jun-ichi Iga¹, Hiroko Kashiwagi³, Hiroshi Komatsu⁴, Hiromi Tagata⁵, Takashi Tsuboi⁶, Shusuke Numata⁷, Hitoshi Iida⁸, Shun Igarashi⁶, Kazutaka Ohi⁹, Kentaro Fukumoto¹⁰, Hiroyuki Muraoka¹¹, Junya Matsumoto³, Kenichiro Miura³, Shu-ichi Ueno¹, Koichiro Watanabe⁶, Ken Inada¹¹, Ryota Hashimoto³, Norio Yasui-Furukori¹² (1. Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Ehime, Japan, 2. Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan, 3. Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan, 4. Department of Psychiatry, Tohoku University Hospital, Miyagi, Japan, 5. Department of Neuropsychiatry, Toho University School of Medicine, Tokyo Japan, 6. Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan, 7. Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University, Tokushima, Japan, 8. Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, 9. Department of Psychiatry, Gifu University Graduate School of Medicine, Gifu, Japan, 10. Department of Neuropsychiatry, School of Medicine, Iwate Medical University, Iwate, Japan, 11. Department of Psychiatry, Kitasato University, School of Medicine, Kanagawa, Japan, 12. Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, Japan)

Keywords:schizophrenia, clozapine, monotherapy, polypharmacy, guideline